title: [Treatment of cancer of the bladder in elderly patients with an intra-arterial chemotherapy and radiotherapy combination: 10-year experience].
abstract: OBJECTIVE
  Analysis of the results obtained in elderly (75 years and older) included a phase II trial combining intra-arterial cisplatin and concurrent radiation into invasive bladder cancer.
  
  
  METHODS
  Thirty-five patients (28 males and 7 females) were accrued from 1985 to 1996. There were 1 Ta, 4 T2, 11 T3A, 12 T3B, 3 T4A, and 4 T4B patients. Nine had unilateral hydronephrosis and two bilateral hydronephrosis. There were 28 transurethral resections which were incomplete in 23 patients. Intra-arterial cisplatin was given as 2-4 hours infusion (60-90 mg/m2) split through both internal iliac arteries on day 1, 14, 21, and 42. Irradiation to the pelvis was started on day 14 and consisted of 40 Gy/20 fractions followed by a boost of 20 Gy/10 fractions to the tumor with margins of 2 cm.
  
  
  RESULTS
  Thirty (86%) completed fully the protocol. One patient died from sepsis secondary to the treatment. The tumor response was evaluable in 29 patients and complete response was observed for 27 of them. Five of these 27 patients had an isolated bladder relapse which was salvaged by cystectomy in two patients. There were 11 deaths from bladder cancer (31% of the patients): 9 from distant metastase, one from local failure, and one from treatment.
  
  
  CONCLUSIONS
  This combined modality yields excellent results with high complete response rate and good tolerance. This approach may therefore be particularly appropriate for the elderly.
authors.affiliation: Service de radio-oncologie, Centre de cancérologie d'Ottawa, Ontario, Canada.
authors.forename: L
authors.initials: L
authors.lastname: Eapen
authors.forename: D
authors.initials: D
authors.lastname: Stewart
authors.forename: L
authors.initials: L
authors.lastname: Grimard
authors.forename: J
authors.initials: J
authors.lastname: Crook
authors.forename: N
authors.initials: N
authors.lastname: Futter
authors.forename: I
authors.initials: I
authors.lastname: Aref
authors.forename: S
authors.initials: S
authors.lastname: Huan
authors.forename: P
authors.initials: P
authors.lastname: Rasuli
authors.forename: R
authors.initials: R
authors.lastname: Peterson
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D008297:Male; D009367:Neoplasm Staging; D011879:Radiotherapy Dosage; D016019:Survival Analysis; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin